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Abstract 
 
USING STRUTURAL ANALYSIS TO INVESTIGATE THE FUNCTION OF 
SUPPRESSOR OF IKK-ε (SIKE) 
By Sean W. McKinley, M.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of 
Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2014 
 
Major Director: Dr. Jessica K. Bell, Ph.D. 
Assistant Professor, Department of Biochemistry & Molecular Biology 
 
The innate immune system provides the body’s first line of defense against 
pathogenic challenge through pathogen recognition and initiation of the immune 
response.  Among the various cellular mechanisms of pathogen recognition in mammals, 
Toll-like receptor 3 (TLR3) recognizes viral dsRNA.  Stimulation of TLR3 signaling 
pathway leads to transcription of pro-inflammatory cytokines and type-1 Interferons.  
Suppressor of IKKε (SIKE) interacts with two kinases in the signaling pathway, IKKε 
and TANK binding kinase 1 (TBK1), inhibiting the transcription of type I interferons. 
Recently, the Bell Laboratory discovered that SIKE blocks TBK1-mediated activation of 
type I interferons by acting as a high affinity, alternative substrate of TBK1. 
	  	  
To further characterize SIKE’s function within the antiviral response, this study 
focused on defining the overall SIKE structure. Using recombinant protein expressed 
from E. coli and purified via immobilized metal affinity chromatography, SIKE crystals 
were obtained from a sample concentrated to 15 mg/ml under several crystallization 
conditions.  Yet, reproducing these results has been difficult.  In this study, we have 
modified the purification scheme to remove an E. coli contaminant, SlyD.  Purification 
under denaturing conditions, removal of soluble proteins, incorporation of ion exchange 
and different IMAC (immobilized metal ion affinity chromatography) resins has been 
tested.  For each scheme, size exclusion chromatography and SDS-
PAGE/Coomassie/silver stain were used to assess purity.  Crystallization trials for 
samples from each purification scheme were completed.  In addition to crystallization 
trials, hydrogen-deuterium exchange (HDX) was investigated, accompanied with pepsin 
digests, in order to further characterize the dynamic structure of SIKE.  
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Chapter 1: Introduction  
  
1.1 Immunology and the Immune Response 
 Immunology is a subdivision of biomedical science that explores all aspects of the 
immune systems found in different organisms.   The main focus of this field is the 
functioning of the immune system in both healthy and diseased states, as well as genetic 
or acquired immune disorders1.  Immunology also involves studying other systems, 
where pathology and clinical symptoms are affected by immune reactions.  The success 
of the immune system depends on its ability to distinguish host (self) cells from foreign 
(non-self) antigens.  The immune system doesn’t normally mount an immune response 
against itself; this is termed “tolerance”.  However, in rare cases tolerance can be lost and 
immune responses are initiated against the host’s cells; this is called auto-immunity1,2.   
The Chinese are credited with making some of the first immunological 
observations, deliberately infecting people with mild forms of small pox to prevent 
infections with deadlier forms and even providing lifelong protection.  After this 
discovery, knowledge and practices moved through Turkey in the late 18th century and 
ultimately to Britain in 1796.  There, British physician, Edward Jenner, published his 
long-term observation that milkmaids exposed to cowpox became protected from 
smallpox1,2.  In his experiments, he exposed a “healthy” 8-year-old boy to cowpox virus 
taken from a milkmaid cowpox pustule by inserting pus into an incision in the boys arm2.  
Cowpox shares antigens with smallpox, but doesn’t cause the same disease; the vaccine 
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worked by initiating an immune response against cowpox antigen, subsequently 
immunizing the boy against smallpox antigen and establishing a smallpox immunity2. 
For the next fifty years, the prevailing theory was that chemical toxins were 
contracted from ill patients, causing the transmission of the disease; the bacteria observed 
were considered to be symptoms of the disease state, not the cause of it2.  It wasn’t until 
the mid-19th century that Friedrich Gustav Jakob Henle, following the ideas of Girolamo 
Fracastoro and Agostino Bassi, began to observe that growth and reproduction of some 
microorganisms within their hosts could be the cause of a disease.  Gustav’s essay, “On 
Miasma and Contagia,” was an early report demonstrating the germ theory of disease.  
“Miasma” was considered to be a poisonous vapor or toxin emitted from infected organic 
matter that can cause a disease.  This became the predominant theory of disease 
transmission until the germ theory of disease greatly changed immunology3. 
Louis Pasteur is traditionally considered as the “father of modern immunology” 
because of his extensive work in the late 19th century on fermentation, spontaneous 
generation, and other areas of microbiology4.  Pasteur led the fields of epidemiology, 
bacteriology, and public health in that time, as well as being the first to establish the 
possibility of anaerobic organisms5.  In his famous work, “Germ Theory of Disease,” 
Louis Pasteur explained his theory that some infectious diseases, such as anthrax, 
cholera, tuberculosis, and smallpox, are caused by microorganisms.  Pasteur is also 
renowned for inventing a rabies vaccine in 18854.   
In 1876, Louis Pasteur’s “Germ Theory of Disease” was proven when Robert 
Koch successfully isolated an infectious bacillus that he showed was the cause of both 
anthrax and cholera.  Koch investigated pathogenicity, developing a set of postulates that 
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are still used in labs today to examine if a disease is caused by a specific virus, bacteria, 
fungi, or parasite.  Koch also worked extensively to develop more efficient staining 
methods, culturing techniques, and was one of the first to demonstrate that unfavorable 
conditions can lead to sporulation in certain bacterial strains to survive6. 
After the breakthrough that diseases are caused by microbes, researchers began 
investigating how host organisms combat these diseases and symptoms.  In 1890, Emil 
von Behring and Shibasaburo Kitasato immunized guinea pigs with heat-treated 
diphtheria toxin; by infecting the animals with a non-lethal form of the pathogen, they 
were able to develop a sufficient immune response to subsequent infections by those 
bacteria.  After its success in the first human trial, it was known as the “first cure” and 
Von Behring was awarded the Nobel Prize in 1901 for this work7.   
Other scientists at this time were also researching different cellular processes.  
Russian zoologist, Elie Metchnikoff, discovered the process of phagocytosis while 
working with starfish larvae.  He realized that this was practically the same process that 
white blood cells perform in the human body to destroy certain potentially harmful 
microbes.  This belief was argued by some of the leading scientists such as Pasteur; 
however, Metchnikoff’s work on phagocytosis won him the Nobel Prize in 19088. 
 Debates arose as to which theory regarding the cellular basis of immunity was 
correct: antibody-mediated immunity or phagocytosis.  Today, they are both recognized 
as fundamental processes of cellular immunity.  The antibody-mediated response is 
associated with the acquired (adaptive) immune response and requires the production of 
specific antibodies to target a particular pathogen.  Germline-encoded gene segments 
have the ability to recombine to synthesize copious amounts of unique, antigen-
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recognizing immunoglobulin9.  This adaptability process requires 3-5 days to complete, 
following the initial infection; however, can result in lifelong immunity to subsequent 
infections by pathogens expressing the same antigen2 (shown in Figure 1). 
 The other process of cellular immunity, phagocytosis, plays a primary role in, 
what is now known as, the innate (non-specific) immune response.  This begins 
immediately after infection and provides the first line of defense against other organisms 
in a non-specific manner.  These responses are mostly limited to defenses that are 
constitutively expressed and readily mobilized1,2.  Germline encoded sensors and 
receptors recognize certain signals and stimulate phagocytic cells to engulf and kill the 
pathogens associated with these signals2.  The innate immune system involves anatomical 
barriers such as epithelial surfaces, low pH levels, and normal flora that prevent infection 
and colonization by invading organisms.  It also contains humoral barriers, for example 
the complement system, interferons, interleukins, and lysozyme, which work as part of 
the inflammatory process when invasive pathogens penetrate tissues.  As proposed by 
Metchnikkoff, neutrophils, macrophages, Natural Killer (NK) cells, and eosinophils 
perform the cellular process of phagocytosis.  These cells are recruited to the site of 
infection where they kill invading organisms extracellularly or phagocytose and kill them 
intracellularly1,2.  The main focus of our lab, and the remainder of this document, is the 
role of the innate immune system and the function of a newly discovered component of 
the anti-viral immune response. 
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Figure 1: Main components of the innate and adaptive immune systems 
 
 
 
Figure	  1:	  Main	  components	  of	  the	  innate	  and	  adaptive	  immune	  systems.	  Components	  of	  the	  immune	  system	  are	  divided	  into	  two	  categories:	  Innate	  immunity,	  (left)	  effective	  during	  initial	  stages	  of	  infection,	  and	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1.2 The Innate Immune System 
 The human body encounters various pathogenic agents each day, yet infections 
are rarely established.  These agents are destroyed within minutes to hours without the 
use of antigen-specific immunoglobulin for recognition1.  The innate immune response 
employs a set of mechanisms to distinguish self from non-self that are thought to be 
older, evolutionarily3. These defense strategies are comprised of anatomical, humoral, 
and cellular barriers, all of which contribute to the first line of defense against 
pathogens3. 
 Anatomical barriers provide the earliest protection of the innate defense 
systems1,2.  These anatomical barriers are characterized by certain mechanical, chemical, 
and biological factors.  Mechanical barriers refer to the epithelial surfaces that form a 
physical barrier that is impermeable to most infectious agents.  These epithelial layers 
include the skin and lining of respiratory, gastrointestinal, and urinary tracts and are held 
together by tight junctions1,2.  Mechanisms used by these barriers to remove bacteria and 
other infectious agents include: desquamation (or shedding) of the skin, oscillation of 
broncho-pulmonary cilia to clear respiratory tract, and the flushing of tears and saliva to 
protect the mouth and eyes3.  Biological factors, such as normal microbial flora, function 
to prevent the colonization of pathogenic bacteria through various methods.  Flora is 
commensal bacterium that can inhibit the establishment of bacterial infections by 
secreting toxic substances or by competing for nutrients or attachment to epithelial 
surfaces1. These commensal bacteria can also stimulate the nearby epithelial cells to 
secrete antimicrobial agents to ward off invasive organisms. Chemical factors 
complement the mechanical barriers in the innate immune response.  Lysozyme and 
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phospholipase help break down the cell wall of bacteria and destabilize bacterial 
membranes.  These are found in saliva, tears, and nasal secretions.  Fatty acids and low 
pH levels inhibit the growth of bacteria and are found on the skin and in the 
gastrointestinal tract. Defensins are antimicrobial agents found in the lungs and 
gastrointestinal tract that destroy microbial cell membranes1,2.  All together, these 
physical, chemical, and biological barriers provide the first stage of defense in the innate 
immune response.   
 Infections, however, can still occur when damage has been done to tissues and 
anatomical barriers are breached.  When a microbe has established an infection, the next 
system of defense employed by the innate immune system is the anti-inflammatory 
response.  This process involves humoral factors like the complement system, 
coagulation system, interferons, interleukins, lysozyme, and lactoferrin/transferrin1,2.  
These factors are constitutively present in serum and are also up-regulated at the site of 
infection, once the infection is recognized by host cells.  The complement system is the 
major non-specific defense mechanism that, once activated, leads to vasodilation, 
recruitment of phagocytic cells, and opsonization and lysis of the organism1.  The 
coagulation system is often activated in situations that involve more tissue damage.  
Products of the coagulation system increase vascular permeability, attract phagocytic 
cells to the site of infection, and can have direct anti-microbial properties.  Lactoferrin 
and transferrin both function by binding iron in the environment.  This is essential for 
bacterial growth and helps prevent infections.  The release of interferons helps to limit 
viral replication in infected cells and lysozyme works to break down bacterial cell walls.  
Interleukins function to induce a fever and initiate the production of acute phase proteins 
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that can have antimicrobial properties.  These factors are present in serum play an 
important role in the inflammation process, once infections have been established.   
 The cellular functions of the innate immune system include the recruitment of 
polymorphonuclear (PMN) eosinophils and macrophages to the site of infection.  
Neutrophils are a type of PMN cell that are recruited to the site of infection to 
phagocytose invading organisms and kill them intracellularly1. Macrophages function 
using phagocytosis and intracellular killing, as well as extracellular killing of infected or 
dysfunctional host cells.  Macrophages also contribute to antigen presentation that is 
required for the induction of specific immune responses.  Natural Killer (NK) cells 
contribute to the killing of virally infected and tumor cells.  Eosinophils contain proteins 
that are effective in killing certain infectious parasites3.  Along with mechanical and 
humoral factors, the cellular defense systems provide a short-lived, non-specific, early 
immune response to control or eliminate infection by pathogenic agents. 
 
1.3 Toll-like receptors: Discovery and Structure 
 The innate immune system uses a unique strategy in order to distinguish self from 
non-self antigens using non-specific means.  Repeating patterns on the pathogen surface 
structure or in nucleic acid sequences are recognized by pattern recognition receptors 
(PRRs).  These receptors identify evolutionarily conserved motifs that are found mainly 
in microorganisms, called PAMPs (pathogen-associated molecular patterns) 1,2,11.  PRRs 
are expressed by various epithelial, endothelial, and immune cells and immediately begin 
mounting an immune response.  Receptors are organized into categories defined by their 
location and function: membrane-bound signaling receptors, cytosolic signaling 
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receptors, membrane-bound phagocytic receptors, or free receptors secreted into the 
circulatory or lymphatic systems1,2.  One class of signaling receptors, Toll-like receptors 
(TLRs), is the focus of research in the Bell Laboratory and will be the basis of the 
remainder of the document.  
 TLRs represent an evolutionarily conserved defense system.  First identified in 
fruit fly embryos, Toll receptors functioned in dorso-ventral patterning during 
embryogenesis.  Christine NÜsslein-Volhard observed underdevelopment in the 
patterning when mutated; her reaction was “Das was ja toll!” meaning, “That was weird!” 
which subsequently gave Toll receptors their name10.  The protein product of the Toll 
gene that causes ventral patterning in fruit fly embryos, known as Dorsal, is a fly 
homologue of the transcription factor NF-κB1,2.  Jules Hoffman observed these mutations 
in adult fruit flies and observed decreased production of antimicrobial peptides and 
increased susceptibility to fungal infections1,10.  This was the first time Toll receptors 
were associated with the host immune system.  Homologues (Toll-like receptors) were 
then identified in mammals by Ruslan Medzhitov and Charles Janeway, and shown to 
function in several host defense mechanisms 1,2,10.  The group determined that TLR 
activation induces NF-κB in a similar manner as interleukin-1 receptors (IL-1Rs) and the 
fruit fly Toll receptors, leading to the expression of inflammatory cytokines2,11.  
 To date, at least 10 members of the TLR family have been identified in mammals 
and are part of a larger superfamily of interleukin-1 receptors (IL-1Rs).  The members of 
this superfamily all have a conserved region of about 200 amino acids in the cytoplasmic 
(C-terminal) region termed the TIR (Toll/IL-1R) domain11. This suggests that both TLRs 
and IL-1Rs signal via shared downstream molecules10,11.  These TIR domains are also 
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observed in plants, which may be evidence that this is a conserved motif that may have 
served immune functions prior to the divergence of plants and animals. 
 In contrast, the extracellular (N-terminal) regions of these TLRs contain leucine-
rich repeats (LRRs), while IL-1Rs have three immunoglobulin domains, which function 
to bind ligands. These extracellular domains are highly variable and are directly involved 
in the recognition of a variety of pathogens1,11,12.  Scientists next sought to identify which 
type of ligands stimulate the receptors: a “danger signal” produced by host cells or a 
microbial molecule released by the pathogen10.  Alexander Poltorak and Bruce Beutler 
observed that were unresponsive to a gram-negative endotoxin component, LPS, which 
they mapped back to a mutation in the TLR4 gene.  To date, the structures of TLR1-6 and 
TLR8 have been solved using x-ray crystallography13.  The variable, extracellular 
domains could now be analyzed to determine the amino acids underlying the 
receptor:ligand interactions.  Three-dimensional structure showed that the LRR domains 
consist of a varying number of repeats, each 22-29 amino acids in length, containing the 
motif XXLXLXX along with other conserved leucines2,11,13.  These domains also contain 
hydrophobic residues spaced at distinct, conserved distances, pointing inward and 
forming a solenoid structure.  TLRs are able to form either homo- or heterodimers, 
depending on the type of ligand.  Each of the ten members of the TLR family recognize a 
variety of evolutionarily conserved PAMPs, such as (but are not limited to) lipopeptides 
(TLR2:TLR1 or TLR2:TLR6 heterodimers), double-stranded RNA (TLR3 homodimer), 
LPS (TLR4 homodimer), flagellin (TLR5 homodimer), single-stranded RNA (TLR7 and 
TLR8 monomer), or CpG-rich unmethylated DNA (TLR9 homodimer) (Figure 2) 1,10,11,12.  
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Signal transduction through TLRs can occur both on the cell surface and in 
intracellular vesicles.  TLRs 1, 2, 4, 5, and 6 are located mainly on the cell surface, while 
3, 8, and 9 are found on the membranes of endosomes and lysosomes13 (Figure 2).  Signal 
transduction for both occurs in the cytosol, allowing their ligand-binding domains to be 
exposed to either vesicular contents or the extracellular environment.  Surface TLRs 
interact largely with microbial membrane components while endosomal TLRs are able to 
interact with genetic material from pathogens that have been internalized and broken 
down13.  Many different types of pathogens can be detected despite the mechanism used 
to establish infections.   
TLR expression is complex and differs between cell types.  Expression is most 
significant in different white blood cell types such as macrophages, mast cells, and 
dendritic cells.  This allows macrophages and mast cells to initiate innate immune 
responses and dendritic cells to initiate adaptive immune responses13. Ultimately, TLR 
signaling leads to activation of interferon regulatory factors (IRFs), activator protein 
1(AP-1), or NF-κB transcription factor family members. These transcription factors are 
responsible for producing the antimicrobial effects; NF-κB and AP-1 mainly induce 
expression of pro-inflammatory cytokines and chemotactic factors while IRFs induce 
expression of antiviral type1 interferons1. The location and activating-ligand of each TLR 
define what products are expressed, antiviral or antibacterial.  
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Figure 2: Human Toll-like receptors and antigens they recognize. 
 
 
 
Figure	  2:	  Human	  Toll-­‐like	  receptors	  and	  antigens	  they	  recognize.	  	  Toll-­‐like	  receptors	  are	  found	  on	  either	  the	  plasma	  or	  endosomal	  membrane,	  activated	  by	  various	  pathogen-­‐associated	  molecular	  patterns.	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1.4 Toll-Like Receptor 3: Role in Innate Immunity 
 The TLR of the pathway focused on for these studies, TLR-3, is expressed among 
different cell types1,2. As previously mentioned, TLR-3 is found on the membranes of 
endosomes and lysosomes and detects genetic material exposed after the pathogen has 
been internalized and digested.  Among all of the Toll-like receptors, it is the only one 
that is capable of recognizing dsRNA14.  Once the vesicular material is identified as 
foreign, a signal is generated to activate transcription factors to initiate an innate immune 
response is initiated.   
 Mammalian TLRs are active when ligand-binding stimulates formation of dimers 
or oligomers3.  Ligand-induced dimerization of two TLR-3 ectodomains brings the two 
cytoplasmic TIR domains into close proximity, allowing them to interact with specific 
adaptor molecules that initiate the intracellular signaling1,2,11.  Combinational use of 
different adaptor molecules allows for diverse and distinct biological effects of activating 
different toll-like receptors.  Four adaptor molecules used by TLRs are: myeloid 
differentiation factor 88 (MyD88), MyD88 adaptor-like (MAL), TIR domain-containing 
adaptor-inducing IFN-β (TRIF), and TRIF-related adaptor molecule (TRAM)1,11.  While 
other TLRs may use one or more of them, TLR-3 interacts with only one, TRIF, to 
induce activation of NF- κB and MAPK (mitogen-activated protein kinases) in MyD-88-
deficient macrophages11.  
TRIF is the most crucial adaptor protein in the TLR-3 pathway and also provides 
a connection to a branch of TLR-4 signaling that converges downstream in the TLR-3 
pathway15.  Overexpression or deficiencies of TRIF alone can have adverse effects on the 
immune response generated by those TLR pathways15.  TRIF has distinct protein-
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interaction motifs that allow the recruitment of various effector proteins, which results in 
one of at least three possible signaling cascades for TLR-3 activation (Figure 3)1,2.   
Two of the three possible signal cascades initiated by TLR-3 activation involve 
the recruitment of TRIF, however, one results in NF-κB expression, while the other 
induces IRF-31,2,15. TRIF recruits TRAF-6 to its N-terminal domain via a specific TRAF-
6-binding sequence, which leads to the recruitment of RIP1 (receptor-interacting protein 
1) kinase to the C-terminal domain of TRIF through interaction of their RIP homotypic 
interaction motifs (RHIMs)1,15,16.  At this point, the two pathways diverge depending on 
the ubiquitination state of RIP1.   
If ubiquitination of lysine 377 on RIP1 kinase does not occur, it will trigger a cell 
death-associated response.  FADD (Fas-Associated with Death Domain protein) and 
Caspase 8 are recruited to complex with RIP1 to initiate downstream signaling.  
Activation of Caspase 8 leads to promotion of cell death by triggering the receptor-
mediated apoptotic pathway2,16.  This outcome suggests that this pathway is an important 
host defense for limiting the spread of viral infections16.   
Ubiquitination of Lysine residue 377 on RIP1 initiates recruitment and binding of 
ubiquitin acceptor proteins, TAK1 (transforming growth factor β-activating kinase 1) and 
TAB2 (TAK binding protein 2)15,16.  Activation of TAK1 causes the complex to be 
released in the cytoplasm to phosphorylate, and activation IKK (IκB kinase complex), a 
heterodimer composed of IKKα and IKKβ subunits, as well as activate of NEMO (NF-κB 
essential modulator).  In turn, the activated IKK complex phosphorylates two serine 
residues of IκBα (Inhibitor of κBα), which is normally sequestering NF-κB complex, 
RelA (p65) and NF-κB1, in a dormant state until this modification15,16.  Phosphorylation, 
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along with further ubiquitination, targets IκBα for degradation by proteasome and allows 
translocation of the NF-κB complex into the nucleus.   Once in the nucleus, it functions 
as a transcription factor, inducing the expression of genes involved in the immune 
response, cellular growth and survival responses, as well as forming an inhibitory 
feedback loop by up-regulating the expression of its own receptor, IκBα2,16,17. 
The third signaling cascade requires the recruitment of effector molecules TRAF1 
(tumor necrosis factor receptor-associated factor 1), TRAF2, TRAF3, and TRAF61,2,15,16.  
These proteins mediate the signal transduction pathway by functioning as molecular 
bridges that bring other effector proteins together.  Once recruited to the activated 
receptors, these proteins mediate the activation of TBK1 (TANK-binding kinase 1)1,2.  
Exclusive interactions of three adaptors: TANK (TRAF-associated NK-κB inhibitor), 
NAP1 (NF-κB activating kinase (NAK)-associated protein 1), and SINTBAD (similar to 
NAP1 TBK1 adaptor), with two kinases: TBK1 and IKKε (IκB kinase epsilon), leads to 
activation of these kinases2,15,16.  TBK1 and IKKε are responsible for phosphorylation 
and activation of certain transcription factors such as IRF-3 and IRF-7.  Seven Ser/Thr 
sites can be phosphorylated near the C-terminus of IRF3, 385SSX9SXSXXXSXTS405.  
Phosphorylation of Ser-396 to Ser-405 induces interaction with CBP/p300, while 
phosphorylation of Ser-385 and Ser-386 activates IRF3 dimerization.  Once it is activated 
and forms a dimer, IRF3 can transmit the signal into the nucleus to initiate the antiviral 
immune response through regulation of type 1 interferons1,2,15,16.  These interferons (IFN-
α and IFNβ) help stimulate macrophages and NK cells to either elicit an anti-viral 
response or a positive feedback loop by binding the IFNα/β receptors to activate the JAK 
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(Janus Kinase)/STAT (signal transducer and activator of transcription) pathway and 
expression of more anti-viral genes2,15.   
  These three TLR-3-mediated signaling pathways initiate recruitment of immune 
cells, inhibition of pathogen replication, induction of apoptosis, and communication of 
danger signals to nearby cells. Because of its importance in innate immunity, our work 
has focused on the pathway involving IRF3 activation, the transcription factor that 
functions in production of type 1 interferons.  In particular, we have examined the 
structure of a recently identified protein, which is known to play a role in this pathway.  
SIKE is found in phosphorylated and un-phosphorylated states; the functions of both 
remain unknown.  As such, understanding the structure of SIKE may provide insight into 
its function in the TLR-3 pathway.   
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Figure 3: TRIF-dependent signaling cascades 
 
 
 
Figure	  3:	  TRIF-­‐dependent	  signaling	  cascades.	  	  Activation	  of	  TRIF	  leads	  to	  three	  possible	  signal	  cascades,	  initiating	  various	  cellular	  processes.	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1.5 Suppressor of IKK-ε (SIKE): Discovery, Structure, and Function. 
 Several innate immune signaling pathways converge to activate TBK1, as 
previously mentioned, through receptor-mediated pathogen detection.  Dysregulation of 
TBK1 has been linked to cancers and autoimmune disorders, intensifying the need to 
understand the regulatory mechanisms used by the proteins in these pathways2,18.  Known 
mechanisms that modify the activity of TBK1 involve altering TBK1 ubiquitination or 
masking phosphorylation sites by interacting proteins in the cascade18,19.  Investigating 
the functions of such interaction partners can reveal information about how the pathway 
is regulated in normal environmental conditions. 
Using a yeast two-hybrid screen with a human B-cell cDNA library and IKKε as 
bait, a previously unknown interaction protein was identified and dubbed SIKE (for 
suppressor of IKKε)19.  SIKE is a 207-amino acid protein encoded by a gene that maps to 
human chromosome 1p13.22,18.  GenBank database searches identified SIKE as an 
evolutionarily conserved protein that is part of an uncharacterized family of proteins like 
fibroblast growth factor receptor 1 oncogene partner 2 (FGFR10P2), which mapped to 
chromosome 12p12.12,18,20.  Although SIKE differs from FGFR10P2 by 40 amino acids, 
they were shown to be about 50% homologous.  Additionally, studies showed that 
FGFR10P2 has the ability to dimerize, associate with coiled-coil structures, and interact 
with cytoskeleton networks of fibroblasts to enhance oral wound healing18,19,20.  Since 
coiled-coil motifs are known to mediate protein-protein interactions, researchers 
questioned if SIKE could oligomerize.  Analysis of SIKE revealed that it had three 
predicted coiled-coil domains, two of which were high probability predicted domains 
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(amino acids 72-102 and 163-197)2,18,19.  Co-immunoprecipitation experiments showed 
that SIKE could interact with itself to form homodimers and oligomers (Figure 4)19. 
It was shown that SIKE formed interactions with IKKε, however, this kinase is 
not detectable under basal physiological conditions, but is induced by activated immune 
cells.  Researchers then questioned whether SIKE could interact with TBK1, which is 
constitutively expressed in most cell types.  Co-immunoprecipitation assays showed that 
SIKE not only interacted with TBK1 under physiological conditions, but it was revealed 
that the high probability coiled-coil domains of SIKE (amino acids 72-207) interacted 
with the coiled-coil domains of TBK1 (amino acids 601-729)19.  This suggests that the 
coiled-coil motifs did mediate interactions between these two proteins.  It also shows that 
the first 72 residues of SIKE are not necessary for interactions with TBK1, but failed to 
show any interactions between SIKE and the kinase domain of TBK12,19.   
In mammalian overexpression systems, it was shown that SIKE associates with 
TBK1 in untransfected cells, but dissociates upon viral infection or TLR3 stimulation18,19.  
Data indicated that SIKE did not disrupt any interactions required by proteins for TLR3-
mediated NF-κB activation, suggesting that SIKE specifically inhibited the IKKε- and 
TBK1-mediated IFN-β activation pathways19.  Subsequent research performed by Andrei 
Medvedev’s group indicated that LPS-induced pathway activation increased levels of 
SIKE mRNA, which suggests that transcription factors activated by these pathways 
control SIKE expression21. 
Aiming to characterize the competition between TBK1 substrates, IRF3 and 
SIKE, the Bell Laboratory showed that SIKE acts as a mixed type inhibitor with respect 
to IRF3 phosphorylation18.  Data showed that both substrates had similar Km values (~50 
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nM) at low concentrations, but SIKE displayed a Km more than 8 times lower (IRF3 = 3.5 
µM; SIKE = 0.4 µM) at higher substrate concentrations.  In other words, at higher 
concentrations, TBK1 has a higher affinity for phosphorylating SIKE than IRF3, thus 
inhibiting IRF3 dimerization, translocation into the nucleus, and regulation of Type 1 
interferon gene transcription.  It was also shown that SIKE is phosphorylated at six sites 
that mimic the phosphorylation motif of IRF3.  This phosphorylation modulates 
TBK1:SIKE interactions and correlates with the initiation of the antiviral response18.  
Once SIKE has been phosphorylated, the affinity of TBK1 for SIKE reduces drastically, 
allowing dissociation of the two proteins.  Currently, the function of phosphorylated 
SIKE remains unknown.  Using these findings, the Bell Lab proposed that SIKE 
functions, not as an inhibitor of TBK1-mediated phosphorylation of IRF3, but as a 
higher-affinity TBK1 substrate (Figure 5).  Due to the fact that phosphorylation requires 
enormous amounts of energy and can cause immense changes in a proteins structure, the 
basis of this research is to investigate the function of phosphorylated SIKE once it has 
been released by the TBK1.  
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Figure 4 Hypothesized domain organization of SIKE and its kinase, TBK1. 
 
 
 
Figure	  4	  Hypothesized	  domain	  organization	  of	  SIKE	  and	  its	  kinase,	  TBK1.	  	  SIKE	  (top)	  is	  207	  amino	  acids	  in	  length	  and	  has	  three	  predicted	  coiled-­‐coil	  domains.	  	  Its	  kinase,	  TBK1	  (bottom),	  is	  729	  amino	  acids	  long	  and	  also	  contains	  two	  coiled-­‐coil	  domains	  that	  are	  thought	  to	  mediate	  interactions	  with	  SIKE.	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Figure 5: SIKE interactions in the TLR3 signaling pathway (Jessica K. Bell). 
 
 
Figure	  5:	  SIKE	  interactions	  in	  the	  TLR3	  signaling	  pathway	  (Jessica	  K.	  Bell).	  
In the TLR3 signaling cascade, SIKE is known to function as a TBK1 substrate and 
subsequently inhibiting phosphorylation of IRF3.  The function of SIKE once it has been 
phosphorylated remains unknown. 
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1.6 Current Study 
To fully comprehend the function of proteins in a cellular mechanism or pathway 
requires in-depth knowledge of their overall structure and amino acid composition.  
Simply knowing pieces of this can only be suggestive of a protein’s function1,18,22.  
Primary amino acid sequences can be used to predict secondary structural elements such 
as membrane-spanning α-helices.  However, a tertiary structure cannot be reliably 
deduced unless the sequence is very similar to a protein whose three-dimensional 
structure is already known22.  A protein’s function can be predicted using other methods, 
such as cellular localization, identifying charged surface areas, or locating any active sites 
or catalytic pockets1,22.  The main technique used to uncover three-dimensional structures 
at atomic level is X-ray crystallography.  
To further characterize SIKE’s function within the antiviral response, this study 
focused on defining the overall SIKE structure through X-ray crystallography. To 
accomplish this, the Bell lab created different constructs in hopes to increase chances of 
obtaining crystals.  Two of the constructs were: a full-length SIKE construct (SIKE FL) 
and a construct that has had the first 71 amino acids removed (SIKE 72); these were the 
two used for this study.  Mutations from serine to alanine were performed on TBK1 
phosphorylation sites for each SIKE construct, known as S6A. This was shown to make 
SIKE more stable and reduced the number of species present in SEC (size exclusion 
chromatography). Using recombinant protein expressed from E. coli and purified via 
immobilized metal affinity chromatography, SIKE crystals were previously obtained 
from a sample concentrated to 15 mg/ml under several crystallization conditions.  Yet, 
reproducing these results has been difficult.   
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In this study, we have modified the purification scheme to remove an E. coli 
contaminant, SlyD.  Purification under denaturing conditions, removal of soluble 
proteins, incorporation of ion exchange and different IMAC resins were tested.  For each 
scheme, size exclusion chromatography and SDS-PAGE/Coomassie/silver stain were 
used to assess purity.  Crystallization trials for samples from each purification scheme 
were completed.  In addition to crystallization trials, Hydrogen-Deuterium exchange was 
investigated, accompanied with pepsin digests, in order to further characterize the 
dynamic nature of SIKE structure. While these studies investigate the properties of 
recombinant SIKE using various methods, the findings as a whole establish a previously 
undefined protocol for SIKE purification that will improve future studies, as well as 
expanding our knowledge of the surface structure of SIKE, which will enhance our 
understanding of its function in the innate immune system.  
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Chapter 2: Materials and Methods 
 
2.1 Bacterial Constructs and Recombinant SIKE expression 
 Constructs used in this study: Full-length SIKE, SIKE 72-207, and their 
corresponding S6A constructs were previously reported2.  For construct expression, 
recombinant pET15b vectors were transformed into BL21-CodonPlus (DE3)-RIPL 
competent E. coli cells following the manufacturer’s protocol (Agilent Technologies).  
A culture of Luria broth (LB) and 100µg/mL ampicillin was inoculated with a 
single colony and left to incubate overnight, shaking at 200rmp at 37oC.  The following 
day, sub-cultures (1:100 dilution) were made in 2-1L flasks containing LB and 100µg/mL 
ampicillin and incubated at 37oC, shaking at 200rpm until they reached an A600≈0.6.  At 
this point, each 1L culture was induced using 1mL of 1M isopropyl-β-galactopyranoside 
(IPTG) and allowed to grow for another 4 hours in the same conditions before harvesting 
the cells.  In addition to those conditions, we investigated the effects of slowing down 
growth by icing for 30 minutes pre-induction, inducing with IPTG, and incubating at 
16oC (200rpm) overnight before harvesting the cells.   
Overnight Express™ Instant LB (auto-induction media) was also used to culture 
bacteria that had been transformed with SIKE constructs.  Prepared using manufacturer’s 
protocol (Novagen), 2-1L cultures of auto-induction media (100µg/mL ampicillin) were 
inoculated, 1:100, using the same regular LB overnight culture grown to an A600≈0.6, as 
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previously mentioned for the normal LB prep.  These 2L cultures were left to incubate 
overnight at 37oC, shaking at 200rpm (no IPTG is needed to stimulate protein expression 
using auto-induction media).   
 
2.2 Harvesting Inclusion Bodies 
2.2.1 Chemical Lysis 
Cells were harvested by centrifugation at 7,000rpm for 20 minutes at 4oC.  Pellet 
was collected and solubilized in a guanidine hydrochloride (GudHCl) buffer (6M 
guanidine hydrochloride, 100mM sodium phosphate (pH8.0), 500mM NaCl, and 1mM 2-
mercaptoethanol) and brought to a pH of 8.0.  After stiffing to solubilize the pellet, cell 
lysates were pelleted through centrifugation at 12,000rpm for 30 minutes at 4oC.  The 
supernatant was mixed with 5mL resin that had been pre-equilibrated in GudHCl buffer. 
 
2.2.2 Freeze-thaw Lysis 
Cells were lysed using a freeze-thaw technique.  Cell pellet was suspended in 
Buffer 1 (100mM sodium phosphate (pH8.0), 500mM NaCl, and 1mM 2-
mercaptoethanol) with added protease inhibitors (complete EDTA free, Roche).  Once in 
solution, tubes were placed in an ethanol/dry ice bath until frozen and then placed in 37oC 
water bath until thawed.  This process was repeated two additional times and then the cell 
lysate was spun down at 14,000rpm for 15 minutes at 4oC.  Pellet was suspended once 
more in Buffer 1 and centrifugation was repeated.  Pellet was collected and re-suspended 
in GudHCl lysing buffer, stirring at room temperature for one hour.  Cell lysates were 
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pelleted through centrifugation at 12,000rpm for 30 minutes at 4oC.  Supernatant was 
then mixed with 5mL resin that had been pre-equilibrated in GudHCl buffer. 
 
2.2.3 Sonication Lysis 
A third technique used to harvest SIKE from the transformed cells was sonication.  
Pellet was suspended in ~75mL Buffer 1 with added protease inhibitors.  While on ice, 
cells were sonicated for 30 seconds (100% power).  This was repeated 10-15 times, 
waiting 1 minute between each sonication, and the resulting lysate was pelleted in a 
centrifuge at 12,000rpm for 20 minutes at 4oC.  Pellet was suspended once more in 
Buffer 1 and centrifugation was repeated.  Pellet was collected and re-suspended in 
GudHCL buffer, stirring at room temperature for one hour.  Cell lysates were pelleted 
through centrifugation at 12,000rpm for 30 minutes at 4oC.  Supernatant was then mixed 
with 5mL resin that had been pre-equilibrated in GudHCl buffer.  
 
2.3 Refolding Denatured SIKE 
2.3.1 Ni-NTA Affinity Resin 
 Ni-NTA agarose resin (Qiagen) was used to bind recombinant protein construct 
containing an N-terminal 6xHistadine tag (pET15b).  5mL of resin was pre-equilibrated 
in the same lysing buffer as the cell lysate.  The cell lysate was then added to the resin 
and left on a rotator for at least one hour at room temperature to batch-bind.  Resin-lysate 
mixture was loaded into a BioRad Econo column and washed with 150mL GudHCl 
buffer.  Protein bound to the resin was refolded on the column using a 40-column-volume 
(CV) reverse gradient of GudHCl buffer to Buffer 1 and eluted using 6 column volumes 
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of elution buffer (Buffer 1 with 500mM imidazole); 6-5mL tubes were collected on ice 
and stored at 4oC.   
 
2.3.2 TALON® Affinity Resin (ClonTech) 
 IMAC using refolded protein was performed using one NiNTA elution fraction 
(E3) that had been dialyzed into TALON® Buffer 1 (50mM sodium phosphate, 300mM 
NaCl, and 1mM 2-mercaptoethanol) to remove imidazole. This was then combined with 
TALON® resin that had been pre-equilibrated in the same TALON® Buffer 1 and left to 
rock at room temperature for at least one hour at room temperature.  The mixture was 
loaded into a BioRad Econo column and washed with 150mL TALON® Buffer 1.  
Protein bound to the resin was eluted using 6 column volumes of TALON® elution 
buffer (TALON® Buffer 1 with 500mM imidazole); 6-5mL tubes were collected on ice 
and stored at 4oC.   
IMAC was performed on TALON® resin with denatured protein, using the same 
procedure used for the NiNTA resin, however, the lysing buffer (6M Guanidine 
Hydrochloride, 50mM sodium phosphate, 300mM NaCl, and 1mM 2-mercaptoethanol) 
and Buffer 1 deviated, slightly, from the Ni-NTA buffers.  Once the cells had been 
harvested and resin had been pre-equilibrated in the lysing buffer, they were combined 
and left on a rotator at room temperature for at least one hour.  Resin-lysate mixture was 
loaded into a BioRad Econo column and washed with 150mL TALON® lysing buffer.  
Protein bound to the resin was refolded on the column using a 40-CV reverse gradient of 
TALON® lysing buffer to TALON® Buffer 1 and eluted using 6 column volumes of 
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TALON® elution buffer (TALON® Buffer 1 with 500mM imidazole); 6-5mL tubes were 
collected on ice and stored at 4oC.   
  
2.4 Purifying and Concentrating Proteins 
2.4.1 Size Exclusion Chromatography 
 Each elution fraction was centrifuged at 14,000xG for 15 minutes to remove any 
precipitate before being loaded on a HiLoad 16/60 Superdex 200 column (GE 
Healthcare) to separate the remaining contents by size.  The buffer used in filtration was: 
50mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 500mM NaCl, and 
1mM 2-mercaptoethanol.  Peak fractions were collected and protein was screened for 
using SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) analysis 
and gels were silver stained to confirm purity.  Pure fractions of each SIKE species were 
combined and concentrated for crystallization trials. 
 
2.4.2 Anion Exchange  
 Using dialysis tubing with a 10,000 Dalton molecular weight cut off, IMAC 
elution fractions were dialyzed overnight in a low-salt ethanolamine buffer (50mM 
ethanolamine (pH9.0), 50mM NaCl, and 1mM 2-mercaptoethanol) and then loaded on 
MonoQ XL ion chromatography column (GE healthcare) to separate remaining contents 
by anion exchange.  Buffer salt concentration was gradually increased to 1M as fractions 
were collected; protein purity was screened using SDS-PAGE and silver staining 
techniques.  Pure fractions from each SIKE species were combined and concentrated for 
crystallization trials. 
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2.4.3 Cation Exchange  
 Using dialysis tubing with a 10,000 Dalton molecular weight cut off, IMAC 
elution fractions were dialyzed overnight in a low-salt sodium acetate buffer (50mM 
sodium acetate (pH 4.5), 50mM NaCl, and 1mM 2-mercaptoethanol) and then loaded on 
HiTrap SP XL ion chromatography column (GE healthcare) to separate remaining 
contents by cation exchange.  Buffer salt concentration was gradually increased to 1M as 
fractions were collected; protein purity was screened using SDS-PAGE and silver 
staining techniques.  Pure fractions from each SIKE species were combined and 
concentrated for crystallization trials. 
 
2.4.4 Concentration via Centrifugation 
 Purified SEC fractions containing the same species were combined into one tube 
and stored at 4oC.  Using Amicon Ultra Centrifugal Units® from Millipore (10,000 
Dalton molecular weight cut off), pooled fractions were concentrated to 15mg/mL (or as 
close as possible) using the manufacturers protocol.  Protein concentration was quantified 
using absorbance at 260nm and 280nm.  Concentrating was stopped when 15mg/mL was 
reached or when precipitate was visible.  To minimize precipitate formation, 1mM 2-
mercaptoethanol or 10% glycerol was added and mixed thoroughly before continuing 
centrifugation. When complete, the concentrated sample was transferred to a sterile, 
Eppendorf® LoBind protein micro-centrifuge tube and stored at 4oC. 
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2.4.5 Concentration via Lyophilization (or Cryodesiccation) 
Purified SEC fractions containing the same species were combined into one tube 
and stored at 4oC.  Using dialysis tubing with a 10,000 Dalton molecular weight cut off, 
the pooled fractions were dialyzed for 24 hours in buffer containing 20mM ammonium 
bicarbonate and 1mM 2-mercaptoethanol.  Solution was then added to a round-bottom 
flask and attached to a lyophilizer to freeze-dry overnight (0.090 mBar and -46oC).  The 
protein-containing powder was collected and solubilized in gel filtration buffer or 50mM 
phosphate buffer (for crystallization trials or MALDI-TOF analysis respectively) and 
brought up to a concentration of 15mg/mL.  Protein concentration was quantified using 
absorbance at 260nm and 280nm.   
 
2.5 Crystallization trials 
2.5.1 Optimized Crystallization Conditions 
 Previously, the lab sent samples of protein to Hauptman Woodward Institute’s 
(HWI) high-throughput screening laboratory to prepare crystal-growth screening 
experiments in 1536-well microassay plates.  Conditions that resulted in the best crystal 
formation (Table 1) were recorded and optimized in the lab with the purpose of obtaining 
X-ray diffraction quality crystals.  All three of the HWI screen hits were subjected to fine 
grid screens to optimize crystal growth, altering the pH and PEG (polyethylene glycol) 
concentration as shown in Table 2.  
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Table 1: HWI Protein Crystallization Screen hits 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HWI Crystal Screen Hits Buffer (0.1M) Salt (0.1M) Precipitant (40% w/v) pH
337 Magnesium chloride hexahydrate Sodium acetate Polyethylene glycol 8,000 5.0
371 Magnesium nitrate hexahydrate Sodium acetate Polyethylene glycol 4,000 5.0
863 Calcium chloride dihydrate Sodium acetate Polyethylene glycol 4,000 5.0
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Table 2: PEG percentage and pH for the 16 optimized crystallization conditions  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30% PEG 
pH 5.1
35% PEG 
pH 5.1
40% PEG 
pH 5.1
42% PEG 
pH 5.1
30% PEG 
pH 5.0
35% PEG 
pH 5.0
40% PEG 
pH 5.0
42% PEG 
pH 5.0
30% PEG 
pH 4.8
35% PEG 
pH 4.8
40% PEG 
pH 4.8
42% PEG 
pH 4.8
30% PEG 
pH 4.6
35% PEG 
pH 4.6
40% PEG 
pH 4.6
42% PEG 
pH 4.6
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2.5.2 Paraffin Oil Drop 
 Crystallization Trays were set up using 72-well Terasaki Plates (Greiner Bio-
One).  Wells were submerged using ~8mL of Paraffin oil before adding 2µL of each 
condition into its designated well.  Concentrated protein sample was centrifuged at 
14,000xG for 15 minutes to remove any precipitated protein and 2µL was carefully added 
to each well containing the optimized solutions.  Plates were covered with a plastic lid 
and left untouched for ~3 days and then observed for crystal growth each day.  Scores 
were made based on the amount and type of precipitate seen.  
 
2.5.3 Sitting Drop  
 Crystallization screens were set up using a 96-well deep well plate.  Selected 
conditions from various Qiagen and Hampton Research Crystallization Screen Kits 
(Table 3) were used to screen with SIKE 72 S6A (3.95mg/mL) for crystal formation.  
About 0.5mL of each selected condition was dispensed in the reservoir of its designated 
well.  0.2µL of the protein was loaded into the smaller sample well and topped with 
0.2µL of the condition from the reservoir. The plate was carefully covered with optically 
clear sealing film and left untouched for ~3 days before being observed for crystal 
growth.  Scores were made based on the amount and type of precipitate seen. 
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Table 3: Qiagen/Hampton Research screen kits and their corresponding Screen 
Hit/condition numbers used in sitting drop crystallization trials. 
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2.5.4 HWI screen 
 A sample of SIKE 72 S6A (12.9 mg/mL) and one sample of plain filtration buffer 
were sent to HWI’s High-Throughput Crystallization Lab to be screened with their 
available conditions and photographed daily for crystal formation.  0.2µL of the protein 
sample was combined with 0.2µL of each HWI condition; a control was also set up using 
0.2µL of plain buffer instead of protein sample.  These wells were photographed weekly 
and observed electronically for the appearance of crystals or changes in precipitate 
formation.   
 
2.6 Hydrogen-Deuterium Exchange 
 Total volume of protein needed was determined by the amount of time points 
desired (~2 µL for each).  Protein samples (between 4 and 12mg/mL) were diluted, 2:18, 
with deuterium oxide (2H2O or D2O) at room temperature, and a timer was started.  At 
each scheduled time point, 20µL of exchanged sample was removed and quenched with 
180µL of TFA-d (deuterated trifluoroacetic acid) and immediately frozen on ice.  Time 
points used for our testing were 0sec, 30sec, 1min, 1.5min, 2min, 3min, 5min, 10min, 
15min, 30min, 45min, 1hr, 1.5hr, 2hr, 3hr, 4hr, 5hr, 6hr, 7hr, and 8hr. Exchanged 
samples were stored on dry ice until analyzed.  D2O exchange matrix buffer was made 
(50µL TFA-d, 200µL D2O, 250µL acetonitrile, and 5-10mg sinapinic acid) and used to 
pre-spot MALDI plate for each sample including one for a control (phosphate buffer) and 
one for a calibration (bovine serum albumin (BSA)) sample.  Plate was then vacuumed in 
a desiccator for ~20 minutes until pre-spots were dry.  Results are best when exchange 
between samples and atmosphere is minimized following quenching, so tubes were kept 
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tightly sealed when not in use.  5µL of each exchanged sample was thawed and added to 
5µL of matrix buffer.  This was mixed quickly before plating 2µL on designated pre-spot 
on the plate.  2µL of BSA sample, phosphate buffer sample, and exchange samples from 
each time point were plated twice in case one could not be read properly.  Once complete, 
plate was vacuumed in desiccator for another 20 minutes, until spots are dry.  Time 
points were analyzed using MALDI-TOF (matrix assisted LASER desorption/ionization-
time of flight), taking 1000 profiles for each spot. 
 
2.7 Pepsin Digest 
 Total protein needed for all time points was calculated.  Protein samples were 
diluted 1:100 with 50mM phosphate buffer to the same concentration as the deuterium 
exchange samples after being quenched with TFA-d.  50% immobilized pepsin mixture 
(Pierce) was re-suspended and 0.25mL was added to 4mL of digestion buffer (20mM 
sodium acetate, pH 3.5).  Mixture was centrifuged at 1000xG for 5 minutes.  Supernatant 
was discarded and pellet was re-suspended in another 4mL of digestion buffer before 
another 5 minutes of centrifugation at 1000xG.  Supernatant was discarded and pellet was 
brought up in 0.5mL of digestion buffer.  The pepsin mixture was then added to 0.5mL of 
diluted protein sample and left to incubate by shaking or inversion at 37oC.  At each 
scheduled time point, 50µL was removed and pepsin was separated from the protein 
through centrifugation at 3,000xG for 3 minutes.  Time points used for our testing were 
0min, 1min, 5min, 10min, 15min, 30min, 1hr, 2hr, and 8hr.  Supernatant, containing 
protein sample, was then removed and stored at room temperature until plated.  Pepsin 
digest matrix buffer was made (5-10mg α-cyano-4-hydroxycinnamic acid dissolved in 
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500µL of 50% D2O, 50% acetonitrile, and 0.1%TFA) and used to pre-spot MALDI plate 
for each sample and low-molecular-weight calibration standards.  The plate was then 
vacuumed in the desiccator for ~20 minutes until pre-spots were dry.  5µL of each digest 
time point sample was added to 5µL of matrix buffer.  This was mixed before plating 2µL 
on designated pre-spot on the plate, two spots for each sample were used. Standards were 
plated for low-molecular-weight calibration, along with each time point sample.  Once 
complete, plate was vacuumed in desiccator for another 20 minutes, until spots were dry.  
Time points were analyzed using MALDI-TOF, taking 1000 profiles for each spot.  All 
theoretical fragments that can result from pepsin digest of SIKE 72 S6A were acquired 
(Protein Prospector) used to compare with experimental digest data. 
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Chapter 3: Results 
 
3.1 Original SIKE Expression and Identification of Contamination 
 As indicated in the methods section, the original protocol included protein 
expression in E. coli grown from regular LB, chemical cell lysis in GudHCl, refolding on 
Ni-NTA resin, polishing through SEC, and centrifugal concentration.  Expression of 
SIKE FL S6A was confirmed (after refolding) using SDS-PAGE, showing bands at 
~29kDa (Figure 6a), which is standard for this protein weighing only 25,788 Daltons.  
All gels were silver stained to confirm purity of the sample.  Expression of SIKE 72 S6A 
was confirmed using the same technique.  Typical for this 17,964 Dalton protein, SIKE 
72 S6A bands were seen at ~18kDa (Figure 6b).  Also seen in the SIKE 72 S6A gel is an 
unknown band at ~29kDa (Figure 6b) that eluted in three of the six fractions.  Due to the 
fact that this contaminant could be covered by the bands of interest for the full-length 
construct (also runs at ~29kDa), we chose to continue most of the study using SIKE 72 
S6A to be sure that we collected pure samples only.   
 To further polish the samples by separating them based on size and shape, Ni-
NTA elution fractions were subjected to SEC.  Figure 7a shows an SEC chromatogram 
from one SIKE 72 S6A Ni-NTA elution fraction (E2 from Figure 6b).  The protein that 
eluted first (peaks labeled “1”) represents aggregate SIKE 72 S6A protein, while protein 
that eluted second (peaks labeled “2”) was determined to be monomers/dimers of SIKE 
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72 S6A.  However, SDS-PAGE revealed the existence of the same ~29kDa contaminant 
that was present in the original sample (Figure 7b).  Previously, contamination at this 
level had not been observed and could possibly have been overlooked due to the full-
length protein running at the same molecular weight in SDS-PAGE. In addition to using 
pure SIKE protein for crystallization trials, we elected to devote some time to modifying 
the existing purification procedure to maximize pure protein yield. 
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Figure 6: SDS-PAGE results of unmodified purification protocol and identification 
of contamination.   
 
 
 	  
Figure	  6:	  SDS-­‐PAGE	  results	  of	  unmodified	  purification	  protocol	  and	  
identification	  of	  contamination.	  	  (Top)	  SIKE	  FL	  S6A	  band	  separates	  to	  ~29	  kDa.	  (Bottom)	  SIKE	  72	  S6A	  separates	  to	  18	  kDa,	  uncovering	  the	  contaminant	  that	  separates	  to	  27	  kDa.	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Figure 7: SEC performed on SIKE 72 S6A (Figure 6b, fraction E2), purified using 
the original protocol   
 
 
Figure 7: SEC performed on SIKE 72 S6A (Figure 6b, fraction E2), purified using 
the original protocol.  (Top) Chromatogram showing Peak 1, aggregates of proteins, and 
Peak 2, monomer/dimer SIKE species. (Bottom) SDS-PAGE shows SIKE 72 S6A in all 
fractions and contamination found in peak 2 fractions. 
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3.2 Auto-induction media increased soluble protein yield; growth at 16oC did not 
 One way to amplify the protein yield was to use auto-induction media to induce 
expression of our protein more efficiently.  Different metabolites in the media function to 
promote cell growth to a high density and automatically stimulate protein expression 
from IPTG-inducible lac promoters.  Figure 8 shows SDS-PAGE analysis from 
expressions using the original LB or the new auto-induction media.  The new auto-
induction media successfully increased the overall yield of pure SIKE 72 S6A from an 
average of ~18 mg per 1L of cell culture to over 53 mg per L culture (~3 fold more 
protein).   
Growth at 16oC is known to help reduce aggregation during folding of 
recombinant proteins23.  Once cells reach an OD600=0.6-1.0, cells are immediately put on 
ice to cool before being induced with 1mM IPTG and then grown overnight at 16oC.  
This helps induce cold shock proteins and chaperones that are active at lower 
temperatures.  SIKE is expressed as insoluble protein in inclusion bodies- this approach 
was used to examine if lower temperatures could allow SIKE to be expressed as soluble 
protein.  Nonetheless, this method was unsuccessful in increasing the amount of soluble 
protein and decreasing the amount of aggregate protein (data not shown).  For the 
remainder of these studies, auto-induction media was used for induction of SIKE 
expression in E. coli grown at 37oC.  
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Figure 8: Results of SIKE 72 S6A expression with original LB media and auto-
induction media.   
 
 
 
 
Figure 8: Results of SIKE 72 S6A expression with original LB media and auto-
induction media.  SDS-PAGE shows considerably more SIKE 72 S6A expression using 
auto-induction media (bottom) than regular Luria Broth (top). 
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3.3 Sonication, but not freeze-thaw lysis, decreased amount of soluble contaminant 
 Proteins that are being over-expressed, like SIKE 72 S6A, are often stored inside 
intracellular structures called inclusion bodies24.  These inclusion bodies generally 
contain very little host protein, suggesting that harvesting SIKE protein from inclusion 
bodies could minimize contamination.  Solubility test results showed most of the SIKE 
72 S6A in the insoluble pellet sample, while the contaminant showed up solubilized in 
the supernatant (Figure 9).  Figure 10 shows SDS-PAGE analysis from protein harvesting 
using the original chemical lysing protocol and the new sonication protocol.  Although 
the first three elution fractions still contained the contaminant, the level of contamination 
was reduced.  Freeze-thaw lysis was ineffective in reducing the amount of contaminant 
(data not shown).   For the remainder of these studies, sonication was used to remove as 
much soluble contaminant as possible before harvesting inclusion bodies (insoluble 
portion) for chemical re-suspension. 
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Figure 9: Solubility test results. 
 
 
 
Figure 9: Solubility test results. Most of the SIKE 72 S6A is found in the insoluble 
pellet sample (bottom arrow), while the contaminant showed up solubilized in the 
supernatant (top arrow). 
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Figure 10: Results of SIKE 72 S6A harvesting using chemical or sonication cell lysis.   
 
 
 
 
Figure 10: Results of SIKE 72 S6A harvesting using chemical or sonication cell lysis.  
SDS-PAGE shows more soluble contaminant when chemical lysis was used (top) than 
when sonication is used for cell lysis (botom). 
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3.4 Anion and cation exchange were unsuccessful in separating bacterial 
contaminant from SIKE.   
 Ion exchange chromatography is based on the reversible interaction between a 
charged protein and the oppositely charged chromatography medium used 
(http://www.gelifesciences.com).  Based on the amino acid sequence, the estimated 
isoelectric point (pI) for SIKE 72 S6A is 6.2, so the anion buffer had a pH of 9.0, to 
ensure de-protonation of accessible acid groups; and the cation exchange buffer had a pH 
of 4.5, to ensure protonation of all basic groups.  In this study, elution of proteins used an 
increasing gradient of NaCl to compete with the charge-charge interaction between 
protein and resin.  It was hypothesized that SIKE and the contaminant would elute off of 
the column at different times as the NaCl concentration gradually increased from 50mM 
to 1M.   
Figure 11 shows results from the first anion exchange attempt using IMAC 
elution fraction E1 from an auto-induction/sonication prep (E1 from Figure 10).  SDS-
PAGE and silver staining was used to confirm that the contaminant was successfully 
separated from the target SIKE protein; however, the flow-through was not collected so it 
could not be analyzed and all additional anion exchange trials were all unsuccessful in 
separating the two proteins (data not shown). 
 Figure 12 shows results from a cation exchange attempt using IMAC elution 
fraction E3 from an auto-induction/sonication prep (E3 from Figure 10).  SDS-PAGE and 
silver staining was used to confirm that cation exchange was unsuccessful in separating 
the contaminant from target SIKE protein, as the ~29kDa protein is visible in both 
fractions labeled 1 and 2.  
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Figure 11: Anion exchange performed on SIKE 72 S6A (Figure 10, fraction E1).  
 
 
Figure 11: Anion exchange performed on SIKE 72 S6A (Figure 10, fraction E1). 
Chromatogram shows separation of two species using a MonoQ XL column and a NaCl 
gradient.  Peak 1 (monomer/dimer SIKE species) proved to be pure using SDS-PAGE 
and silver staining techniques.   
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Figure 12: Cation exchange performed on SIKE 72 S6A (Figure 10, fraction E3). 
 
 
Figure 12: Cation exchange performed on SIKE 72 S6A (Figure 10, fraction E3). 
Chromatogram shows separation of two groups using HiTrap SP XL column and a NaCl 
gradient.  Both peak 1 (aggregate protein) and peak 2 (monomer/dimer SIKE species) 
proved to be contaminated using SDS-PAGE and silver staining techniques.   
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3.5 TALON® resin successfully binds SIKE and not contaminant 
 NiNTA elution fraction E2 (from figure 10) was used for IMAC with TALON® 
resin.  SDS-PAGE shows positive binding of both (re-folded) SIKE and SlyD proteins 
(Figure 13).  A significant amount of the SIKE did not bind the column and was found in 
the flow-through sample (FT), but was also visible in all six elution fractions.  
Additionally, contamination was only observed in the first elution fraction (E1). SEC 
analysis of the fractions indicated that the FT was primarily SIKE aggregate protein (data 
not shown), but elution fractions 2-6 were pure samples of SIKE monomer/dimer species 
(Figure 14).  These were combined and concentrated for crystallization trials. 
 SDS-PAGE from IMAC shows positive binding of (denatured) SIKE protein, but 
no binding of (denatured) SlyD with TALON® resin (Figure 15).  SlyD was seen in the 
flow-through portions, indicating that it was present in the sample originally, but failed to 
interact with the cobalt ions on the resin.  SEC and SDS-PAGE analysis of elution 
fractions confirmed the purity of all SIKE samples (Figure 16; E4 results shown).  In 
addition to eliminating contamination, the proportion of SIKE monomer/dimer species 
had increased substantially compared to the trials with re-folded protein samples.  This 
allowed us to focus on concentrating the protein from our peak of interest and continue 
more crystallization trials.   
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Figure 13: SDS-PAGE results from IMAC with refolded proteins and TALON® 
resin (Figure 10, fraction E2).   
 
 
 
Figure 13: SDS-PAGE results from IMAC with refolded proteins and TALON® 
resin (Figure 10, fraction E2).  Resin bound both (re-folded) SIKE and SlyD proteins, 
however, SlyD eluted mainly in the first elution fraction (E1).   
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Figure 14: SEC performed on purified SIKE sample (Figure 10, fraction E2). 
 
 
Figure 14: SEC performed on purified SIKE sample (Figure 10, fraction E2). 
Chromatogram shows elution of SIKE oligomer species, labeled with a number 1.  SDS-
PAGE/silver stain performed on Peak 1 fractions confirm that fractions E2-E6 were 
purified SIKE 72 S6A protein   
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Figure 15: SDS-PAGE results from IMAC with denatured proteins and TALON® 
resin.   
 
 
 
Figure 15: SDS-PAGE results from IMAC with denatured proteins and TALON® 
resin.  Resin bound denatured SIKE only; SlyD can be seen in the soluble supernatant 
portion (Sol.) before IMAC, and flow-through portion (FT) that did not bind the resin. 
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Figure 16: SEC performed on purified SIKE sample (Figure 15, fraction E4). 
 
 
 
Figure 16: SEC performed on purified SIKE sample (Figure 15, fraction E4). 
Chromatogram shows Peak 1 (aggregates of SIKE protein) and Peak 2 (SIKE 
monomer/dimer species).  SDS-PAGE performed on fractions confirms the purity of our 
samples. 
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3.6 Concentration of SIKE 72 S6A and crystallization trials 
 SEC fractions were pooled according to when they eluted during SEC in order to 
separate different SIKE species (monomer/dimer, aggregate, etc).  Centrifugation 
concentration (with 10,000 Da molecular weight cut off filter) was used to remove buffer 
from the pooled fractions.  Concentration was stopped immediately when any precipitate 
became visible in the sample, because further centrifugation would most likely precipitate 
more of the soluble protein.  Through numerous expression and protein harvesting 
procedures, final concentrations ranged anywhere from less than 1mg/mL to over 
20mg/mL, however, concentrations over 10mg/mL were rarely achieved for SIKE 72 
S6A samples (data not shown).  As soon as centrifugation was stopped, crystallization 
trays were set. 
Prior to this current study, a sample of SIKE 72 S6A was sent to HWI to be 
screened using high-throughput crystallization methods and examined with 1,534 
different conditions.  Crystal formation was observed in various conditions, three of 
which were chosen for optimization and further crystallization trials: 337, 371, and 863 
(Table 2.1).  All three conditions contained sodium acetate salt (0.1M) dissolved in buffer 
(pH 5.0) and PEG (polyethylene glycol) 4,000 or PEG 8000 (40%w/v).  These were 
optimized to find the most favorable condition for SIKE crystal formation by altering the 
pH and PEG concentrations, making 16 different conditions from each HWI condition 
(Table 2.2).   
 Vapor diffusion experiments were completed using sitting drop plates and various 
crystal screening kits to identify additional crystallization conditions.  No single-crystal 
formation was observed in any of the sitting drop plates with SIKE 72 S6A concentrated 
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to 3.95mg/mL (data not shown).  However, amorphous microcrystalline structures and 
needle-like structures were observed in numerous conditions for all five screens (data not 
shown).   
Batch crystallization experiments were conducted to minimize any influence from 
the outside environment by covering the conditions with paraffin oil.  Figure 17 shows 
examples of SIKE 72 S6A crystals that were obtained prior to identification of SlyD 
contamination (top images) and SIKE 72 S6A precipitate that was observed in most wells 
during the most recent protocol-modifying purification trials (bottom images).  Original 
SIKE 72 S6A crystals were rod shaped and formed from areas of dense protein 
precipitation.  For the majority of recent trials, protein precipitation was observed in 
almost every condition.  The volume of precipitated protein observed in each well 
increased with higher concentrations of protein samples, yet X-ray diffraction quality 
crystals were rarely observed.  Only two crystals were observed in batch crystallization 
trials during this study (Figure 18); however, they were not collected for any seeding or X 
ray diffraction experiments.  Both crystals were seen using protein sample obtained from 
the protocol modified up to this point only. 
To improve protein concentration, lyophilization was performed as a dehydration 
method to evaporate buffer from the sample, leaving only protein and any other solutes.  
Once completed, the remaining powder was brought up to ~15mg/mL in either 50mM 
phosphate buffer (for MALDI experiments) or gel filtration buffer (to set up 
crystallization plates).  Not all of the protein was soluble, however this method greatly 
increased both the final concentrations and volumes of the pure protein samples.  Final 
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purified SIKE 72 S6A samples ranged from 10-15mg/mL (data not shown) and were 
used for further structural analysis.  
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Figure 17: Previous and current crystallization trials. 
  
 
 
Figure 17: Previous and current crystallization trials. Top row, Crystals (indicated by 
white arrows) obtained prior to the identification of SlyD contamination.  Bottom row, 
precipitate observed in current crystallization trials with the modified protocol.  
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Figure 18: Crystals from current SIKE 72 S6A trials. 
 
 
 
 
Figure 18: Crystals from current SIKE 72 S6A trials. Crystals (indicated by white 
arrows) obtained using the procedure with all protocol modifications up to this point 
except lyophilization.  
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3.7 Mass Spectrometry and Structural Analysis 
In addition to crystallization trials, Hydrogen-Deuterium exchange was 
investigated, accompanied with pepsin digests, in order to further characterize SIKE 
structure.  To confirm that this method could be useful, 0 and 24 hour HDX were 
performed for both SIKE FL S6A (Figure 19) and SIKE 72 S6A (Figure 20).  After 24 
hours, an increase in molecular weight was observed for both constructs, indicating that 
elucidation of structural information is possible through additional amide exchange, 
digest, and analysis experiments.  The overall increase in molecular weight was observed 
to be 144 Daltons for the full-length construct (13,032 to 13,176 Daltons), and 293 
Daltons for the truncated construct (17,886 to 18,179 Daltons). 
 To uncover structural information, fast, medium, and slow exchange of different 
amide protons in the protein’s 3-demensional structure was investigated.  Figure 21 
shows the increase in molecular weight over 8 hours of HDX with SIKE 72 S6A.  A large 
portion (~60%) of the total exchange occurred within the first 30 minutes, however, 
additional deuterium exchange was observed between 1-4 hours and 5-6 hours.  The data 
suggest that a stable tertiary structure exists, protecting some portion of hydrogen from 
exchangingreadily.   
 In order to identify the location of HDX, pepsin digests must be completed with 
both protein that has undergone exchange and protein that has not.  Un-exchanged SIKE 
72 S6A protein was digested with pepsin and sampled at time points between 0-2 hours 
and at 8 hours.  Spectra from each time point up to 2 hours are shown in Figure 22 and 
display successful protein digestion; at 8 hours, the protein was fully digested (data not 
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shown).  This data will be used to determine a time point for reproducible digestion that 
allows for identification of the largest percent of SIKE peptides.   
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Figure 19: Hydrogen-deuterium exchange for SIKE FL S6A (0 and 24hr). 
 
 
 
Figure 19: Hydrogen-deuterium exchange for SIKE FL S6A (0 and 24hr).  Change in 
molecular weight of SIKE FL S6A due to hydrogen-deuterium exchange was observed 
using MALDI from 0 hours (red line) to 24 hours (purple line).  
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Figure 20: Hydrogen-deuterium exchange for SIKE 72 S6A (0 and 24hr). 
 
 
 
Figure 20: Hydrogen-deuterium exchange for SIKE 72 S6A (0 and 24hr).  Change in 
molecular weight of SIKE 72 S6A due to hydrogen-deuterium exchange was observed 
using MALDI from 0 hours (red line) to 24 hours (purple line). 
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Figure 21: Deuterium exchange 8-hour time course for SIKE 72 S6A. 
 
 
 
Figure 21: Deuterium exchange 8-hour time course for SIKE 72 S6A.  Change in 
molecular weight of SIKE 72 S6A due to hydrogen-deuterium exchange was measured 
over an 8-hour time course. 
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Figure 22: Pepsin digest of SIKE 72 S6A (0-2 hours) 
 
Figure 22: Pepsin digest of SIKE 72 S6A (0-2 hours).  SIKE 72 was digested with 
pepsin for the indicated time periods; peaks signify peptide fragments. 
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Chapter 4: Discussion 
 
TLR-3-mediated signaling (through TBK1) initiates the innate immune response 
by recruiting immune cells to the site of infection, inhibiting pathogen replication, 
inducing apoptosis of infected cells, and communicating danger signals to other nearby 
cells 1.  Because of its importance in innate immunity, many studies concentrate on the 
pathway involving IRF3 activation, the transcription factor that functions in production of 
type 1 interferons.  SIKE, a recently identified protein, is thought to play a role in this 
pathway and has been the focus of study.   
SIKE is an evolutionarily conserved, 207-amino acid protein that is part of an 
uncharacterized family of proteins like fibroblast growth factor receptor 1 oncogene 
partner 2 (FGFR10P2)2,18,20.  It was shown that SIKE associates with TBK1 under normal 
physiological conditions, but dissociates upon viral infection and TLR3 stimulation18,19.  
SIKE did not disrupt any interactions required by proteins for TLR3-mediated NF-κB 
activation, suggesting that SIKE specifically inhibited the IKKε- and TBK1-mediated 
IFN-β activation pathways19.  In addition, previous fluorescent microscopy studies show 
SIKE (fused to GFP) accumulating in actin/cytoskeleton-like structures at the cell 
periphery18.  It is hypothesized that SIKE, in response to pathogen challenge, functions in 
cytoskeletal rearrangement through phosphorylation by TBK1.   
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Seeking to characterize the competition between TBK1 substrates, IRF3 and 
SIKE, the Bell Laboratory previously determined that SIKE functions as a mixed type 
inhibitor with respect to IRF3 phosphorylation18.  Study of its protein composition 
indicated that SIKE could be phosphorylated at six different sites, four of which resemble 
phosphorylation sites on IRF325-27. Using these findings, the Bell Lab proposed that SIKE 
functions, not only as an inhibitor of TBK1-mediated phosphorylation of IRF3, but also 
as a TBK1 substrate (Figure 5).  It is believed that SIKE, acting as a substrate, inhibits the 
ability of TBK1 to phosphorylate IRF3, thus inhibiting type 1 interferon production18.  
The function of phosphorylated SIKE once it has been released by the kinase remains 
unknown and is the basis of this research.  As such, understanding the structure of SIKE 
through crystallographic and mass spectrometric methods may provide insight into its 
function in the TLR-3 pathway mediated by IRF3 activation.   
 In the current study, SIKE FL S6A and SIKE 72 S6A (~18 kDA) were 
successfully expressed using the original protein preparation protocol, however 
contamination by an unknown protein was identified in our samples (Figure 6b).  Due to 
the fact that this contaminant ran at the same molecular weight in SDS-PAGE as the full-
length construct (both ~29kDa, Figure 6), we chose to continue most of the study using 
SIKE 72 S6A to be sure that we collected pure samples only.  The unknown protein was 
found to contaminate E1-E3 from SEC trials, leaving only three pure SIKE fractions (E4-
E6) for crystallization trials and structural analysis.  Protein that eluted first off of the 
SEC column (peaks labeled “1”) represents aggregate SIKE 72 S6A protein, while 
protein that eluted second (peaks labeled “2”) was determined to be monomers/dimers of 
SIKE 72 S6A. Supporting these results, SIKE’s peptide sequence and predicted structure 
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suggest that it can interact with itself to form multimers such as dimers or tetramers.  The 
contaminated fractions were used in various experiments with the goal of developing a 
more efficient protocol for the purification of SIKE 72 S6A. 
 To amplify yield for inducible protein expression in E. coli, auto-induction media 
was tested.  Different metabolites in this media function to promote cell growth to a high 
density and automatically stimulate protein expression from IPTG-inducible T7 lac 
promoters28,29.  This serves as an advantage by eliminating the need to monitor the 
growth of cell cultures after inoculation.  Glucose in the media prevents uptake of lactose 
until the glucose is depleted, which is typically mid to late log phase.  At that point, the 
lactose is taken up by the cells and converted into allolactose by β-galactosidase.  
Allolactose binds the lac repressor and causes it to release from the DNA.  The T7 RNA 
polymerase can then bind and begin to induce genes controlled by the lac promoter.  
Such timely induction results in an increase in protein expression and overall yield.  Once 
the concentration of lactose becomes low, glycerol in the media serves as the late energy 
source and the lac promoter is no longer induced29.  In our experiments, auto-induction 
media successfully increased the yield of protein by almost 3 fold (Figure 8).  Although 
the media efficiently increased protein expression, contamination was still observed in 
SEC elution fractions E1-E3. 
One obstacle with the over-expression of recombinant protein in bacterial cells is 
formation of cytoplasmic aggregates in inclusion bodies30.  At higher temperatures, 
aggregation of proteins is driven by hydrophobic interactions23.  Growth at 16oC is 
known to help reduce aggregation during folding by increasing the activity of cold shock 
protein that function as chaperones to aid in protein folding23,30.  One disadvantage is that 
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a sudden decrease in temperature slows replication, transcription, and translation.  
Ultimately, this method proved unsuccessful in increasing the amount of soluble protein 
and decreasing the amount of aggregate protein (data not shown).  For the remainder of 
these studies, E. coli was grown at 37oC as noted in the original protocol.  
Proteins being over-expressed are often stored inside intracellular structures 
called inclusion bodies24.  These inclusion bodies generally contain very little host 
protein, suggesting that harvesting SIKE protein directly from inclusion bodies could 
minimize contamination.  One method used to isolate inclusion bodies is to lyse the 
plasma membrane through a series of flash freezing and thawing31.  Fragmentation of the 
membrane allows inclusion bodies to be easily harvested through centrifugation, 
separating them from any soluble contents.  One possible disadvantage is that the 
procedure could result in protein degradation or precipitation32.  In this study, freeze-thaw 
lysis proved ineffective in reducing the amount of contaminant in SIKE 72 S6A samples 
(data not shown).  Furthermore, overall SIKE 72 S6A protein yield was less than that of 
the original protocol.   
 Another method recommended for harvesting protein from cell cultures, 
sonication, uses a metal probe that generates ultrasonic waves to shear the plasma 
membrane and release inclusion bodies24,33.  The inclusion bodies can then be harvested 
through centrifugation and solubilized to release the enclosed protein.  One disadvantage 
of sonication is excess heat generated from the high-energy waves can damage proteins, 
lowering the final protein yield.  Solubility test results showed most of the SIKE 72 S6A 
in the insoluble pellet sample, while the contaminant separated to the soluble supernatant 
(Figure 9), suggesting that this method may be useful in isolating the protein from the 
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contaminant.  Although fractions E1-E3 still contained the contamination, the overall 
level of contaminant was reduced in each of the three fractions (Figure 10).  For the 
remainder of these studies, sonication was used to remove as much soluble contaminant 
as possible before harvesting inclusion bodies (insoluble portion) for chemical lysis. 
 Ion exchange chromatography is based on the reversible interaction between a 
charged protein and the oppositely charged chromatography medium used 
(http://www.gelifesciences.com).  Small differences in the surface charges of two 
proteins causes them to elute at different points during the process.  The surrounding 
buffer pH largely influences a protein’s surface charge, as well as possible interactions 
that the protein can make.  For anion exchange, the buffer pH should be at least one unit 
higher than the pI of the protein of interest to allow it to bind the positively charged solid 
support.  For cation exchange, the buffer pH should be at least one unit below the pI of 
the protein of interest so it can bind the negatively charged solid support.  Based on the 
amino acid sequence, the estimated pI for SIKE 72 S6A is 6.2, so the anion exchange 
buffer had a pH of 9.0 and the cation exchange buffer had a pH of 4.5.  In this study, 
elution of proteins used an increasing gradient of NaCl to compete with the proteins 
binding to the column.  As the NaCl concentration was gradually increased from 50mM 
to 1M, different elution patterns for SIKE and the contaminant were hypothesized.   
 Although positive separation of the two species was observed for the first anion 
exchange trial (Figure 11), all subsequent trials proved to be unsuccessful (data not 
shown).  Additionally, all cation exchange trials were unsuccessful in separating the two 
proteins based on charge (Figure 12). Together, these results demonstrate that SIKE 72 
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S6A cannot be successfully separated from the contaminant by either anion or cation 
affinity chromatography.   
  Further research on the ~27kDa contaminant helped us identify it as a genome-
encoded E. coli protein, named SlyD34.  SlyD is a small (22,853 Daltons), cytosolic 
protein that has 14 histidine residues clustered at the C-terminal end of the peptide 
sequence (Figure 23).  This amino acid composition results in contamination of 
purification procedures that use Ni-NTA resin to bind his-tagged proteins.   
Analysis of Ni-NTA elution fractions by SDS-PAGE showed positive binding 
(E1-E3) of both SIKE and SlyD proteins to the resin (Figure 6).  Clontech Laboratories, 
Inc. advertises a resin, TALON®, which uses Co2+ metal ions instead of Ni2+ ions to bind 
histidine residues.  Contaminated Ni-NTA fractions were used to assess the efficiency of 
the resin to bind (already refolded) SIKE 72 S6A.  A significant amount of SIKE did not 
bind the resin and was found in the flow-through, however, SlyD contamination was 
limited to the first elution fraction (Figure 13).  SEC analysis of the FT indicated that it 
was primarily SIKE aggregate protein (data not shown), but elution fractions 2-6 from 
these trials were determined to be pure SIKE monomer/dimer species (Figure 14).  These 
were combined and concentrated for crystallization trials. Together, these results suggest 
that the SlyD residues are still interacting with the ions on the resin.   
 The amino acid sequence of SlyD (Figure 23) shows the histidine residues spread 
throughout the C-terminus, suggesting that separation using TALON® resin may be 
enhanced if the proteins were denatured and refolded on this resin, as opposed to using 
previously-refolded protein.  SDS-PAGE from IMAC shows positive binding of 
denatured SIKE protein, but not denatured SlyD with TALON® resin (Figure 15).  SlyD 
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was seen in the flow-through portions, indicating that it was present in the sample 
originally, but failed to interact with the cobalt ions on the resin.  In addition to 
eliminating contamination, SEC showed the proportion of SIKE monomer/dimer species 
had increased substantially compared to the aggregate portion (Figure 16).  This allowed 
us to focus on concentrating the protein from our peak of interest and continue 
crystallization trials.   
 Proteins that eluted at different times during SEC were pooled separately in order 
to separate SIKE species (monomer, dimer, etc).  Following coentrifugation, final sample 
concentrations ranged from less than 1mg/mL to over 20mg/mL, however, SIKE 72 S6A 
samples over 10mg/mL were rarely attained (data not shown).  When centrifugation was 
stopped, crystallization trays were set. 
In supersaturated solutions, small protein particles (seeds) stimulate separation of 
the solute from the solvent; this is called precipitation.  This process is influenced by the 
contents, concentration, and pH of a solution, as well as environmental conditions.  The 
point when the concentration becomes ideal for crystal formation is known as the 
“nucleation point.”  Structure and charge of a protein determine the possible ways in 
which they can interact when they precipitate out of a solution35.  Crystal formation 
requires the diffusion of protein from an aqueous liquid to a pure-solid crystalline phase.  
It is known that specific 3-dimensional repeating protein patterns (monomers/ multimers, 
complexes, subunits, etc) form crystals if they precipitate in well-defined size and 
shape36.  Precipitation that occurs with a less-ordered arrangement of protein species 
produces amorphous structures.  To help draw the protein out of solution, precipitants can 
be used in the crystallization experiments.   
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Prior to this current study, a sample of SIKE 72 S6A was sent to HWI to be 
screened using high-throughput crystallization methods and examined with 1,534 
different conditions.  Crystal formation was observed in various conditions, three of 
which were chosen for optimization and further crystallization trials: 337, 371, and 863 
(Table 1).  All three conditions contained sodium acetate salt (0.1M) dissolved in buffer 
(pH 5.0) and PEG 4,000 or PEG8000 (40%w/v).  These were optimized to find the most 
favorable condition for SIKE crystal formation by altering the pH and PEG 
concentrations, making 16 different conditions from each HWI condition (Table 2.2).   
 Vapor diffusion experiments were completed using sitting drop plates and various 
crystal screening kits to identify additional crystallization conditions. Sitting drop plates 
use a reservoir well for the crystallization condition and a small well for the protein 
sample that is covered by the same condition in the reservoir well.  This method is 
designed to allow diffusion of water vapor out of the sample, increasing the concentration 
of the protein (as well as the precipitant) until equilibration is achieved, ideally around 
the nucleation point35.  No single-crystal formation was observed in any of the sitting 
drop plates with SIKE 72 S6A concentrated to 3.95mg/mL (data not shown).  However, 
amorphous microcrystalline structures and needle-like structures were observed in 
numerous conditions for all five screens.  Analysis of those conditions revealed certain 
common denominators: TRIS or HEPES as the buffer, PEG 4000 or 8000 (25-30% w/v) 
as the precipitant, and ammonium sulfate or sodium acetate as the salt.  This was similar 
to the results from HWI, suggesting that these might be favorable conditions for 
obtaining SIKE 72 S6A crystals, but protein concentration may be too low. 
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Batch crystallization experiments were conducted to minimize any influence from 
the outside environment by covering the conditions with paraffin oil.  Vapor 
diffusion/equilibration is minimized; therefore this method requires protein to be 
introduced directly to conditions around its nucleation point.  Beginning 3 days after the 
trays were completed (to allow time for any crystal formation), plates were observed 
daily.  Although crystals were obtained from crystallization trials before the identification 
of SlyD contamination (Figure 17, top row), current batch crystallization trials have 
mostly been unsuccessful in producing x-ray diffraction quality crystals with SIKE 72 
S6A samples from the modified protocol (Figure 17, bottom row).  Original SIKE 72 
S6A crystals were rod shaped and formed from areas of dense protein precipitation.  For 
the majority of recent trials, protein precipitation was observed in almost every single 
condition.  The volume of precipitated protein observed in each well increased with 
higher concentrations of protein samples, yet no X-ray diffraction quality crystals were 
observed.  This suggested that pure protein samples still might not be concentrated 
enough to allow any crystal formation. 
To improve protein concentration, lyophilization was performed as a dehydration 
method to evaporate water from the sample, leaving only protein and any other solutes.  
Once completed, the remaining powder was brought up to ~15mg/mL in either 50mM 
phosphate buffer (for MALDI experiments) or gel filtration buffer (to set up 
crystallization plates).  Not all of the protein was soluble, however this method greatly 
increased both the final concentrations and volumes of the pure protein samples.  Final 
purified SIKE 72 S6A samples ranged from 10-15mg/mL (data not shown) and were 
used for more crystallization trials and additional structural analysis.  
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In addition to crystallization trials, Hydrogen-Deuterium exchange was 
investigated, accompanied with pepsin digests, in order to further characterize the 
location of HDX using Mass Spectrometry.  Native proteins are typically found in tightly 
folded conformations; understanding these structures is essential to infer a protein’s 
function.  One method used to understand protein conformation is to use hydrogen-
deuterium exchange followed by pepsin digestion and peptide analysis by mass 
spectrometry.  Deuterium (D2) is an isotope of hydrogen that freely exchanges with 
hydrogen atoms on proteins.  The extent to which peptides in the protein are shielded 
from the solvent, and whether they participate in intra-molecular hydrogen bonding 
determine the rate at which the amide protons undergo exchange37.  By identifying where 
HDX is possible in the SIKE sequence, we identify solvent-exposed or flexible structural 
regions. 
To confirm that this method could be useful, 0 and 24 hour exchanges were 
performed for both SIKE FL S6A (Figure 19) and SIKE 72 S6A (Figure 20).  After 24 
hours, an increase in molecular weight was observed for both constructs, indicating that 
elucidation of structural information is possible through additional peptide exchange, 
digest, and analysis experiments.  The overall increase in molecular weight was observed 
to be 144 Daltons for the full-length construct (13,032 to 13,176 Daltons), and 293 
Daltons for the truncated construct (17,886 to 18,179 Daltons).  
 To uncover structural information, time points from 0 hours to 8 hours were used 
in deuterium exchange to determine when fast, medium, and slow exchange occurs for 
SIKE 72 S6A.  Protons exposed to the solvent generally exchange with the environment 
faster than ones buried inside the structure.  Identifying amino acids/ peptides located on 
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the surface requires uncovering which residues underwent fast exchange.  Over the first 
30 minutes, deuterium atoms had already replaced ~164/293 (56%) of the protons in 
SIKE 72S6A available for exchange (using 24hr. as “full exchange;” Figure 20).  
Analysis of SIKE 72 S6A peptide sequence reveals that ~179 amide protons are available 
for fast exchange, 17 of which are located on arginine/lysine side chains.  It is known that 
amide protons of arginine/lysine are not as easily exchanged, leaving ~162 protons that 
(theoretically) can be readily exchanged.  Together, these results support the hypothesis 
that different amino acids/peptides are exchanging hydrogen atoms at different rates.  
Furthermore, exchange for SIKE 72 S6A displayed a step-wise pattern, consistent with 
known (folded) proteins that undergo deuterium incorporation (Figure 21).   
In addition to exchange, pepsin digests were performed to identify the ideal time 
for SIKE digestion to yield adequately sized peptides for mass spectrometry analysis.  An 
ideal time is one that allows for the highest percent of peptide recovery for analysis, as 
well as one that is reproducible.  Ultimately, the proteins that have undergone fast, 
medium, or slow exchange will be digested for the same time to yield the same set of 
peptides for each sample.  Mass spectrometry analysis on the peptides allows comparison 
of exchanged and un-exchanged samples to identify which peptides exchanged more and 
when that exchange occurred.  All together, this information will help us locate the 
peptides within the 3-dimensional protein structure that underwent exchange.  
Pepsin digests of SIKE 72 S6A were performed for at time points between 0 and 
2 hours, as well as one at 8 hours.  Mass spectrometry analysis showed successful 
digestion of protein, revealing fragments of various sizes between 500 and 5,000 Daltons 
(Figure 22).  A database search on the Protein Prospector website with the SIKE 72 S6A 
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sequence revealed every potential peptide fragment that could be created from pepsin 
digest of SIKE 72 (data not shown).  Using this information, the ideal time for protein 
digestion will be determined that yields an appropriate amount of fragments sufficient for 
mass spectrometry analysis.  With the ideal time point determined, SIKE 72 S6A protein 
that has already undergone exchange will be digested and analyzed with mass 
spectrometry.  Molecular weight changes between exchanged and un-exchanged peptide 
fragments will indicate the amount of deuterium that has been exchanged on that specific 
peptide.  Determining which peptides exchanged deuterium helps pinpoint the fragment 
within the overall 3-dimensional structure of the protein that is accessible for exchange.  
Peptides that undergo the fastest exchange are (most likely) positioned such that amide 
hydrogen atoms are more exposed to the exchange solvent.  The peptides observed to 
exchange the least amount are (most likely) buried within the protein, making it difficult 
to exchange hydrogen atoms with deuterium atoms in the solvent.  Currently, only digest 
of un-exchanged SIKE 72 S6A have been completed; subsequent digest for exchanged 
protein and peptide fragment analysis will be needed to infer any information about the 
proteins surface structure. 
In this study, the purification of SIKE 72 S6A revealed an E. coli contaminant, 
later identified as SlyD.  The purification scheme was modified to remove contamination 
and increase the quality of protein samples for crystallization trials.  Auto-induction 
media was effective in amplifying protein yield by over 3 fold. Harvesting inclusion 
bodies by sonication (not freeze-thaw lysis) decreased the overall amount of SlyD in 
IMAC fractions, however, contamination was still observed in the same samples.  Cation 
and anion affinity chromatography were both ineffective in separating the two proteins.  
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TALON® resin bound both denatured SIKE 72 S6A and SlyD, however, only SIKE 72 
S6A bound the resin under denaturing conditions, allowing successful separation from 
the contaminant.  Concentration issues were answered through the use of lyophilization 
techniques, in place of ultrafiltration.  Crystallization trials for samples from each 
purification scheme were completed, but no X-ray diffraction quality crystals were 
observed.  In addition to crystallization trials, Hydrogen-Deuterium exchange 
accompanied with pepsin digests, in order to further characterize the SIKE structure 
where initiated. Additional exchange and digest trials must be completed to conclude any 
structural information regarding the surface area of SIKE 72 S6A.   
While these studies investigate the properties of recombinant SIKE using various 
methods, the findings as a whole establish a previously undefined protocol for SIKE 
purification that will further future structural studies.   
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Figure 23: Amino acid peptide sequence for E. coli protein, SlyD.    
 
 
 
Figure 23: Amino acid peptide sequence for E. coli protein, SlyD.   Highlighted in red 
are 14 histidine residues located in the C-terminus of the protein sequence that cause it to 
contaminate purification procedures that use Ni2+ ions to bind his-tagged proteins.   
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